Groupama Asset Managment Acquires 400,680 Shares of Repligen Co. (NASDAQ:RGEN)

Groupama Asset Managment grew its holdings in Repligen Co. (NASDAQ:RGEN - Free Report) by 12,321.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 403,932 shares of the biotechnology company's stock after purchasing an additional 400,680 shares during the period. Groupama Asset Managment owned about 0.72% of Repligen worth $58,142,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in RGEN. UMB Bank n.a. boosted its position in Repligen by 49.1% during the fourth quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company's stock valued at $48,000 after purchasing an additional 110 shares during the last quarter. Oppenheimer & Co. Inc. acquired a new stake in shares of Repligen during the 4th quarter valued at about $216,000. Worldquant Millennium Advisors LLC grew its stake in shares of Repligen by 11.9% in the 3rd quarter. Worldquant Millennium Advisors LLC now owns 50,276 shares of the biotechnology company's stock valued at $7,482,000 after buying an additional 5,337 shares in the last quarter. Van ECK Associates Corp increased its holdings in Repligen by 7.8% in the fourth quarter. Van ECK Associates Corp now owns 42,226 shares of the biotechnology company's stock worth $6,078,000 after buying an additional 3,066 shares during the last quarter. Finally, Stephens Investment Management Group LLC raised its position in Repligen by 7.4% during the fourth quarter. Stephens Investment Management Group LLC now owns 536,801 shares of the biotechnology company's stock valued at $77,267,000 after acquiring an additional 37,057 shares in the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the stock. TD Cowen assumed coverage on shares of Repligen in a research note on Monday, February 10th. They set a "buy" rating and a $200.00 price target on the stock. HC Wainwright reissued a "buy" rating and set a $180.00 target price on shares of Repligen in a research report on Friday, February 21st. Royal Bank of Canada boosted their price target on Repligen from $203.00 to $205.00 and gave the stock an "outperform" rating in a research report on Friday, February 21st. Evercore ISI initiated coverage on Repligen in a report on Tuesday, March 18th. They set an "in-line" rating and a $155.00 price objective on the stock. Finally, JPMorgan Chase & Co. raised their price objective on Repligen from $190.00 to $200.00 and gave the company an "overweight" rating in a research note on Friday, February 21st. Seven analysts have rated the stock with a hold rating and eight have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $178.64.

Repligen Stock Performance

Shares of Repligen stock traded down $9.76 during midday trading on Friday, hitting $111.94. The company had a trading volume of 1,826,070 shares, compared to its average volume of 686,321. The stock has a market cap of $6.29 billion, a PE ratio of -219.49, a P/E/G ratio of 4.54 and a beta of 0.95. Repligen Co. has a 1-year low of $106.78 and a 1-year high of $182.52. The business's 50 day simple moving average is $150.03 and its two-hundred day simple moving average is $147.58. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76.

Repligen (NASDAQ:RGEN - Get Free Report) last posted its quarterly earnings data on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.41 by $0.03. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. The company had revenue of $167.55 million for the quarter, compared to the consensus estimate of $167.58 million. As a group, equities analysts predict that Repligen Co. will post 1.72 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Margaret Pax bought 250 shares of the business's stock in a transaction that occurred on Monday, March 17th. The stock was acquired at an average cost of $150.69 per share, for a total transaction of $37,672.50. Following the completion of the purchase, the director now owns 1,043 shares of the company's stock, valued at $157,169.67. This trade represents a 31.53 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 1.20% of the company's stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.